Peptide · GLP-1 receptor agonist
Liraglutide
An earlier, once-daily GLP-1 receptor agonist peptide, authorised for type 2 diabetes and for weight management.
Approved medicineAuthorised by a regulator, available on prescription.
- Legal status · US
- Approved medicine
- Evidence in people
- Molecule
- GLP-1 receptor agonist
- In sport
- Not named on the WADA list
- Status checked
Regulatory status · United States
This describes the position in the United States. Rules in European Union differ; an approved peptide medicine there is in its national register.
An approved prescription medicine, including generic versions. Its authorised products are in the ordinary catalogue.
Authorised products
| Brand | Authorised for | How it is given | First US approval |
|---|---|---|---|
| Victoza | Type 2 diabetes | Injection, once a day | 2010 |
| Saxenda | Weight management | Injection, once a day | 2014 |
Doses, warnings and who should not use it are on each product’s official label, linked from its page.
Every authorised product in European UnionWhat changed, and when
First US approval, as Victoza, for type 2 diabetes.
Approved for chronic weight management, as Saxenda.
What to be careful about
Different brands of the same substance are authorised for different uses at different doses. The brand on the pen matters.
Sources
Regulatory positions change. This page states the date it describes, and nothing on it is legal or medical advice.